Long-Term Health and Pregnancy Planning
At a Glance
People with FRTS4 and HNF4A-MODY need lifelong kidney, bone, and diabetes monitoring. Before pregnancy, specialists should review medications and kidney health, plan fetal growth checks, and prepare newborn glucose monitoring because an HNF4A variant can cause fetal overgrowth and low blood sugar.
Because Fanconi Renotubular Syndrome 4 (FRTS4) is a life-long, multi-system condition, your medical care will change as you move through different stages of life. While childhood focuses on growth and bone health, adulthood brings a shift toward managing chronic kidney function and, for many, planning for a family.
A Lifetime of Surveillance
Consistent monitoring is the “gold standard” for care. Research from a 25-patient cohort showed that many children exhibited kidney decline before age 10, and all adults in that study reached Chronic Kidney Disease (CKD) Stage 3, though individual risk and progression rates vary widely [1].
There is no universally validated FRTS4 surveillance schedule. Your nephrology and endocrinology teams will individualize monitoring based on your age, eGFR, and recent results. This often includes checking:
- Kidneys: eGFR (filtration rate), bicarbonate, potassium, and blood pressure [1][2].
- Bones: Phosphate, PTH, Calcium, Alkaline Phosphatase, and growth velocity [3].
- Imaging: Renal ultrasound to check for calcium deposits (nephrocalcinosis) [4].
- Diabetes Care: Standard diabetes screenings for retinal (eye) and cardiovascular complications [5].
- Other Symptoms: Formal auditory, liver, or heart testing if clinically indicated by your specific variant or family history [6][7].
Planning for a Healthy Pregnancy
If you have HNF4A-MODY, pregnancy requires urgent preconception discussions with an Endocrinologist, a Nephrologist, and a Maternal-Fetal Medicine (MFM) specialist. Because this is an autosomal dominant condition, there is a 50% chance of transmission from a parent with the variant to each child. A genetic counselor can discuss reproductive options.
- The Medication Shift: Do not stop or switch medication without a supervised plan. Sulfonylureas cross the placenta and can over-stimulate the baby’s pancreas [8]. A thorough preconception review is needed; insulin is commonly preferred when treatment must be changed, but the exact plan depends on your kidney function and glycemic control [8]. Kidney medications (like certain blood pressure drugs) and alkali therapy also require a safety review.
- Kidney Stability: Pregnancy puts extra strain on the kidneys. Patients face risks for blood-pressure problems, preeclampsia, preterm birth, and potential shifts in kidney function. You will need close nephrology monitoring for proteinuria, bicarbonate, and potassium [2].
- Fetal Macrosomia: If the fetus inherits the HNF4A variant, they may produce too much insulin in the womb, which acts as a growth hormone. This can lead to a significantly higher birth weight [8][9]. Frequent “growth scans” (ultrasounds) are used to monitor the baby’s size.
The First 48 Hours: The Newborn Phase
When a baby is born to a parent with an HNF4A variant, the first two days require a pre-delivery written plan. Even if maternal blood sugar was perfectly controlled, the baby may have inherited the variant and be producing too much of their own insulin [9].
- Neonatal Hypoglycemia: A portion of newborns with this variant will have dangerously low blood sugar (hypoglycemia) shortly after birth [10][11].
- The Safety Plan: Your delivery should take place at a hospital with the capability to provide the level of neonatal glucose monitoring and treatment anticipated. The baby will likely need blood sugar checks before feedings. If their sugar is low, they may require intravenous (IV) glucose or a medication called diazoxide to stabilize them, guided by specialist consultation [12][13].
While these risks are significant, most HNF4A newborns transition out of this “over-production” phase within weeks or months, provided they receive careful monitoring and support [14]. Monitoring through adulthood ensures that if the cycle turns toward HNF4A-MODY later in their own life, they are already under the care of a team that knows their history.
Common questions in this guide
How often should someone with FRTS4 have health checks?
What should I do before trying to conceive with HNF4A-MODY?
Are diabetes and kidney medicines safe during pregnancy?
What pregnancy risks should someone with FRTS4 discuss?
What are the chances of passing an HNF4A variant to my child?
How is a newborn monitored if a parent has an HNF4A variant?
Get notified when new evidence is published on Fanconi renotubular syndrome 4 with maturity-onset diabetes of the young.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Phenotypic Spectrum of HNF4α-Associated Fanconi Renotubular Syndrome.
Emma F, Böckenhauer D, Mallett AJ, et al.
Kidney international reports 2026; (11(8)):106616 doi:10.1016/j.ekir.2026.106616.
PMID: 42440446 - 2
Renal tubular acidosis type 4 in pregnancy.
Jakes AD, Baynes K, Nelson-Piercy C
BMJ case reports 2016; (2016()).
PMID: 26989116 - 3
Rickets guidance: part II-management.
Haffner D, Leifheit-Nestler M, Grund A, Schnabel D
Pediatric nephrology (Berlin, Germany) 2022; (37(10)):2289-2302 doi:10.1007/s00467-022-05505-5.
PMID: 35352187 - 4
A Case of Hyperinsulinemic Hypoglycaemia Associated with Atypical Fanconi Renal Tubulopathy Syndrome Caused by an HNF4A Variant.
Garriga-Edo S, Peris-Serra L, Ríos Duro H, et al.
Case reports in nephrology and dialysis 2026; (16(1)):10-19 doi:10.1159/000549545.
PMID: 41488815 - 5
Maturity Onset Diabetes of the Young (MODY): French National Diagnosis and Care Protocol (PNDS, Protocole National de Diagnostic et de Soins).
Dubois-Laforgue D, Donadille B, Ciangura C, et al.
Orphanet journal of rare diseases 2026; (17(Suppl 1)).
PMID: 42227416 - 6
HNF4A-related Fanconi syndrome in a Chinese patient: a case report and review of the literature.
Liu J, Shen Q, Li G, Xu H
Journal of medical case reports 2018; (12(1)):203 doi:10.1186/s13256-018-1740-x.
PMID: 30005691 - 7
Heterozygous recurrent HNF4A variant p.Arg85Trp causes Fanconi renotubular syndrome 4 with maturity onset diabetes of the young, an autosomal dominant phenocopy of Fanconi Bickel syndrome with colobomas.
Sheppard SE, Barrett B, Muraresku C, et al.
American journal of medical genetics. Part A 2021; (185(2)):566-570 doi:10.1002/ajmg.a.61978.
PMID: 33251707 - 8
Management of sulfonylurea-treated monogenic diabetes in pregnancy: implications of placental glibenclamide transfer.
Shepherd M, Brook AJ, Chakera AJ, Hattersley AT
Diabetic medicine : a journal of the British Diabetic Association 2017; (34(10)):1332-1339 doi:10.1111/dme.13388.
PMID: 28556992 - 9
Management of pregnancy in women with monogenic diabetes due to mutations in GCK, HNF1A and HNF4A genes.
Crowley MT, Paponette B, Bacon S, Byrne MM
Frontiers in genetics 2024; (15()):1362977 doi:10.3389/fgene.2024.1362977.
PMID: 38933924 - 10
Neonatal hypoglycaemia in the offsprings of parents with maturity-onset diabetes of the young (MODY).
Maly J, Urbanova J, Musil V, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2025; (38(6)):570-576 doi:10.1515/jpem-2025-0042.
PMID: 40287849 - 11
A Novel HNF4A Mutation Causing Three Phenotypic Forms of Glucose Dysregulation in a Family.
Chandran S, Rajadurai VS, Hoi WH, et al.
Frontiers in pediatrics 2020; (8()):320 doi:10.3389/fped.2020.00320.
PMID: 32670997 - 12
Diazoxide and Continuous Glucose Monitoring as Treatment in a Neonate with Hyperinsulinemic Hypoglycemia due to HNF4A Mutation
Sotiriou G, Xinias S, Diamantidou V, et al.
Journal of clinical research in pediatric endocrinology 2025; doi:10.4274/jcrpe.galenos.2025.2025-4-12.
PMID: 40960027 - 13
Exceptional diazoxide sensitivity in hyperinsulinaemic hypoglycaemia due to a novel HNF4A mutation.
Arya VB, Kalitsi J, Hickey A, et al.
Endocrinology, diabetes & metabolism case reports 2019; (2019()).
PMID: 31096182 - 14
Prolonged episodes of hypoglycaemia in HNF4A-MODY mutation carriers with IGT. Evidence of persistent hyperinsulinism into early adulthood.
Bacon S, Kyithar MP, Condron EM, et al.
Acta diabetologica 2016; (53(6)):965-972 doi:10.1007/s00592-016-0890-9.
PMID: 27552834
This page is for informational purposes only and does not constitute medical advice. Pregnancy, medication changes, and newborn glucose planning for FRTS4 should be individualized with your endocrinologist, nephrologist, maternal-fetal medicine specialist, and newborn care team.